Clinical trial
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory…
NCT00390156 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00390156 |
|---|---|
| Title | Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors |
| Official title | A Phase I Trial of Imatinib, Bevacizumab, & Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, cyclophosphamide, imatinib |
| Enrollment | 35 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Oct 19, 2006 |
| Last update posted | Jul 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: